Increased Revenue and Profit
Revenue increased by 4.6% to JPY 578.5 billion. Operating profit increased by 3.5%, and net income increased by 2.1% compared to the previous year.
Successful R&D Milestones
The global Phase III trial for orforglipron showed success, and new projects such as MINT91 and AUBE00 began Phase I trials.
Strong Sales Performance
Domestic sales increased by 2.8%, and overseas sales increased by 7.3%. Actemra exports were particularly strong.
New Investments
An investment of JPY 80 billion to build a new research building at the Ukima site, focusing on environmentally friendly equipment.